"What we aim to do is take small ideas from the clinical interaction between pharmacists, physicians and their patients and turn them into big ideas for the greater patient and physician community," Baum said. "Our hope is that this legislation will ultimately benefit patients by increasing access to life saving medications and other lower cost compounded drug options, all made to the highest standards."
ABOUT IMPRIMIS PHARMACEUTICALS
Imprimis Pharmaceuticals, Inc. (IMMY) is a pharmaceutical company focused on the commercial development of novel drug formulations and drug delivery technologies. Imprimis believes in the power of the clinical interaction of one patient, one physician and one pharmacist to build novel therapeutic approaches that have broad market appeal. Imprimis assesses drug formulations created by pharmacists and physicians for a specific patient's use using a proprietary and rigorous evaluation process, the Asset Review Methodology (ARM™), in order to assess potential for commercialization. Following this evaluation process, which may include additional clinical development, Imprimis may choose to pursue FDA approval for a drug formulation through the FDA's Section 505(b)(2) development pathway, or make its treatment options available to the market through pharmacy compounding. In addition, Imprimis expects to seek partnerships with wholesalers in order to make its drug delivery technologies available to compounding pharmacies across North America. The Company's current focus is in the Ophthalmology, Wound Management, Urology and Pain therapeutic areas.
SAFE HARBORThis press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Imprimis' ability to acquire, develop, commercialize and market new formulations and technologies, enter into strategic alliances and transactions, including arrangements with pharmacies, physicians and healthcare organizations, commercialize its formulations and technologies, obtain intellectual property protection for its assets, accurately estimate its expenses and cash burn, and raise additional funds, as well as the success of additional research and development activities related to its formulations and technologies, the projected size of the potential market for its technologies and formulations, unexpected new data, safety and technical issues, regulatory and market developments impacting compounding pharmacies and the pharmaceutical industry, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Contact:
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts